

24th February 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

• Avelumab + Axitinib	1
• Axitinib	6
• Cabozantinib	9
• Everolimus	0
• Lenvatinib + Everolimus	1
• Lenvatinib + Pembrolizumab	2
• Nivolumab monotherapy	3
• Nivolumab + Cabozantinib	7
• Nivolumab + Ipilimumab	0
• Pazopanib	0
• Pembrolizumab monotherapy	2
• Pembrolizumab + Axitinib	0
• Radiotherapy only	N/A

This radiotherapy service is delivered by University Hospitals Sussex NHS Foundation Trust, and their email contact details are as follows: UHSussex.foi@nhs.net

• Sunitinib	1
• Temsirolimus	0
• Tivozanib	0
• Other active systemic anti-cancer therapy	0
• Palliative care only	Section 12 (1) applied.

East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection

(Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- **Avelumab + Axitinib (Bavencio + Inlyta)** 1
- **Cabozantinib (Cometriq)** 5
- **Nivolumab (Opdivo)** 0
- **Nivolumab + Cabozantinib (Opdivo + Cometriq)** 6
- **Nivolumab + Ipilimumab (Opdivo + Yervoy)** 0
- **Lenvatinib + Pembrolizumab (Kisplyx + Keytruda)** 1

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- **Nivolumab (monotherapy)** 0
- **Nivolumab + Ipilimumab** 0
- **Nivolumab + Cabozantinib** 1
- **Avelumab + Axitinib** 0
- **Lenvatinib + Pembrolizumab (Kisplyx + Keytruda)** 1
- **Cabozantinib (Cometriq)** 1

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Procedure	Procedure Description	No. Patients
M10.4	ENDOSCOPIC CRYOABLATION OF LESION OF KIDNEY	1
M02.1	NEPHRECTOMY AND EXCISION OF PERIRENAL TISSUE	2
M02.5	NEPHRECTOMY NEC	4
M02.2	NEPHROURETERECTOMY NEC	2
M03.9	UNSPECIFIED PARTIAL EXCISION OF KIDNEY	5
TOTAL PATIENTS		14

Please note the above figures are for the period 1st November 2025 – 31st January 2026.

Cont.../

Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

We currently have one study open for the treatment of renal cancer as follows:

The PARTIAL study: A randomised trial of the clinical and cost effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma IRAS 318662

Number of recruits: 2

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm